J&J's IMAAVY Becomes First FDA-Approved Treatment for Warm Autoimmune Hemolytic Anemia

Johnson & Johnson (NYSE: JNJ) won FDA approval for IMAAVY (nipocalimab-aahu) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening autoantibody disease in which the immune system destroys its own red blood cells. The approval, announced August 24, covers adults and pediatric patients 12 and older currently or previously treated with corticosteroids. JNJ closed at $273.04 on August 24.

The decision rests on the Phase 2/3 ENERGY study (NCT04119050), where roughly three times as many patients on the approved 30 mg/kg intravenous dose achieved a durable hemoglobin response versus placebo by 24 weeks. Treated patients posted a mean hemoglobin increase of 1 g/dL within the first week and a 3.5-point higher mean FACIT-Fatigue score at Week 24, meaning less fatigue. Among responders, median time to first hemoglobin response was 4.1 weeks versus 12.1 weeks for placebo. The most common adverse reactions were peripheral edema, diarrhea, and fever.

Why It Matters

wAIHA has never had an approved therapy. The roughly 1 in 8,000 Americans living with the condition have cycled through off-label corticosteroids and broad immunosuppressants that suppress the entire immune system without touching the pathogenic IgG autoantibodies driving red blood cell destruction. Patients face a 20-30% higher risk of death plus a higher risk of blood clots, kidney failure, and infection.

IMAAVY is a selective neonatal Fc receptor (FcRn) blocker that lowers circulating IgG autoantibodies while preserving B-cell function, the same mechanism behind its April 2025 approval in generalized myasthenia gravis. The label adds a second indication to J&J’s FcRn franchise and extends nipocalimab’s reach across the autoantibody space, where it is also in Phase 3 for lupus, Sjögren’s disease, and hemolytic disease of the fetus and newborn. We covered nipocalimab’s first FcRn win in lupus in our JASMINE analysis.

What Happens Next

The near-term story is commercial. IMAAVY’s gMG launch already competes with argenx’s Vyvgart, and the wAIHA label opens a market where no rival is approved. For a company of J&J’s size the read-through is modest; the real watch item is whether nipocalimab’s Phase 3 readouts in lupus, Sjögren’s, and maternal-fetal disease broaden the franchise beyond these first two labels. The approval followed FDA Priority Review granted earlier this year, and full ENERGY results were presented at the European Hematology Association meeting in June.